EU OKs Danaher Acquisition of GE Healthcare's Biopharma Business
December 18 2019 - 1:27PM
Dow Jones News
By Giulia Petroni
The European Union on Wednesday approved Danaher Corp.'s (DHR)
acquisition of GE Healthcare Life Sciences' biopharma business,
subject to conditions.
The European Commission said Danaher committed to sell
businesses that posed competition concerns. The acquisition is
conditional on Danaher's compliance.
In February, General Electric Co. (GE) agreed to sell the
business to Danaher for about $21 billion.
Both Danaher and the GE Healthcare Life Sciences' biopharma
business are active in the manufacturing of products and services
used in bioprocessing industries and compete in other life-sciences
areas.
Write to Giulia Petroni at giulia.petroni@wsj.com
(END) Dow Jones Newswires
December 18, 2019 13:12 ET (18:12 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Danaher (NYSE:DHR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Danaher (NYSE:DHR)
Historical Stock Chart
From Apr 2023 to Apr 2024